Uma Prabhakar

4.0k total citations · 1 hit paper
41 papers, 3.1k citations indexed

About

Uma Prabhakar is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Uma Prabhakar has authored 41 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 12 papers in Immunology and 11 papers in Molecular Biology. Recurrent topics in Uma Prabhakar's work include Cancer Immunotherapy and Biomarkers (5 papers), T-cell and B-cell Immunology (5 papers) and Cytokine Signaling Pathways and Interactions (5 papers). Uma Prabhakar is often cited by papers focused on Cancer Immunotherapy and Biomarkers (5 papers), T-cell and B-cell Immunology (5 papers) and Cytokine Signaling Pathways and Interactions (5 papers). Uma Prabhakar collaborates with scholars based in United States, United Kingdom and Japan. Uma Prabhakar's co-authors include Hugh M. Davis, Alberto Gabizón, William C. Zamboni, Piotr Grodzinski, David C. Blakey, Hiroshi Maeda, Omid C. Farokhzad, Rakesh K. Jain, Eva M. Sevick‐Muraca and Simon T. Barry and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Uma Prabhakar

40 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Challenges and Key Considerations of the Enhanced Permeability and Retention Effect for Nanomedicine Drug Delivery in Oncology

2013 1.2k citations Uma Prabhakar et al. profile →

Peers

Countries citing papers authored by Uma Prabhakar

Since Specialization

Citations

This map shows the geographic impact of Uma Prabhakar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Uma Prabhakar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Uma Prabhakar more than expected).

Fields of papers citing papers by Uma Prabhakar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Uma Prabhakar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Uma Prabhakar. The network helps show where Uma Prabhakar may publish in the future.

Co-authorship network of co-authors of Uma Prabhakar

This figure shows the co-authorship network connecting the top 25 collaborators of Uma Prabhakar. A scholar is included among the top collaborators of Uma Prabhakar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Uma Prabhakar. Uma Prabhakar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The anti‐interleukin‐6 antibody siltuximab down‐regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study 2011 ·The Prostate ·Jayaprakash D. Karkera, Hannes Steiner, Weimin Li, (unknown), Patrizia Moser, Sabine Riethdorf, Manjula Reddy, Thomas A. Puchalski, (unknown), Uma Prabhakar, Klaus Pantel, Ming Qi, Zoran Čulig	93
2	Pharmacokinetic and Pharmacodynamic Modeling of an Anti–Interleukin-6 Chimeric Monoclonal Antibody (Siltuximab) in Patients with Metastatic Renal Cell Carcinoma 2010 ·Clinical Cancer Research ·Thomas A. Puchalski, Uma Prabhakar, Qun Jiao, Birge Berns, Hugh M. Davis	86
3	A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer 2010 ·British Journal of Cancer ·JF Rossi, Sylvie Négrier, Nicholas D. James, Ivo Kocák, Robert D. Hawkins, Hugh M. Davis, Uma Prabhakar, Xiang Qin, Peter F.A. Mulders, Birge Berns	152
4	A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia. 2008 ·PubMed ·Bertram Wiedenmann, Peter Malfertheiner, Helmut Friess, Paul S. Ritch, James C. Arseneau, Giovanni Mantovani, Francesco Caprioni, Eric Van Cutsem, D. J. Richel, Mark DeWitte, Ming Qi, Don Robinson, Bob Zhong, Carla de Boer, (unknown), Uma Prabhakar, Robert Corringham, Daniel D. Von Hoff	122
5	A clinical study assessing the tolerability and biological effects of infliximab, a TNF-α inhibitor, in patients with advanced cancer 2008 ·Annals of Oncology ·Ewan Brown, Kellie A. Charles, Susan Hoare, Ron Rye, (unknown), (unknown), (unknown), Uma Prabhakar, M T Nakada, Robert Corringham, Mark DeWitte, C. Sturgeon, David Propper, Frances R. Balkwill, John F. Smyth	140
6	Multiplexed Cytokine Sandwich Immunoassays Clinical Applications 2005 ·Humana Press eBooks ·Uma Prabhakar, (unknown), Bruce E. Miller, Hugh M. Davis	16
7	Co-expression of IL-12 receptors along with CXCR3 and CD25 on activated peripheral blood T lymphocytes 2005 ·Cellular Immunology ·Manjula Reddy, Jackson Wong, Cuc Davis, Uma Prabhakar	3
8	Reviews Preclinical Safety and Immune-Modulating Effects of Therapeutic Monoclonal Antibodies to Interleukin-6 and Tumor Necrosis Factor-α in Cynomolgus Macaques 2005 ·Journal of Immunotoxicology ·Pauline L. Martin, Joel B. Cornacoff, Uma Prabhakar, Thomas Löhr, George Treacy, Jessica E. Sutherland, (unknown), (unknown)	16
9	Cutaneous lymphocyte antigen expression on activated lymphocytes and its association with IL-12R (β1 and β2), IL-2Rα, and CXCR3 2005 ·Cellular Immunology ·Manjula Reddy, Cuc Davis, Jackson Wong, Uma Prabhakar	8
10	A pilot study on safety and pharmacokinetics of infliximab for the cancer anorexia/weight loss syndrome in non-small-cell lung cancer patients 2004 ·Supportive Care in Cancer ·Aminah Jatoi, James R. Jett, Jeff A. Sloan, Paul J. Novotny, Joyce Ford, Uma Prabhakar, Charles L. Loprinzi	26
11	Validation and comparative analysis of a multiplexed assay for the simultaneous quantitative measurement of Th1/Th2 cytokines in human serum and human peripheral blood mononuclear cell culture supernatants 2004 ·Journal of Immunological Methods ·Uma Prabhakar, (unknown), Manjula Reddy, (unknown), Susan Spitz, Charles Pendley, Hugh M. Davis, Bruce E. Miller	68
12	Pharmacokinetic/pharmacodynamic (PK/PD) modeling and trial simulations to guide dose selection with CNTO 328, a chimeric anti-IL-6 monoclonal antibody (MAb), in patients with renal cell carcinoma (RCC) 2004 ·Journal of Clinical Oncology ·Haishan Jang, Uma Prabhakar, (unknown), James M. Ford, (unknown), Hugh M. Davis, (unknown)	1
13	Simultaneous quantification of proinflammatory cytokines in human plasma using the LabMAP™ assay 2002 ·Journal of Immunological Methods ·Uma Prabhakar, (unknown), Hugh M. Davis	162
14	Down regulation of kidney neutral endopeptidase mRNA, protein and activity during acute renal failure: Possible mechanism for ischemia-induced acute renal failure in rats? 1999 ·Molecular and Cellular Biochemistry ·Ponnal Nambi, Hsiao-Ling Wu, Uma Prabhakar, Louis B. Hersh, M. Gellai	18
15	A Novel Human Bone Marrow Stroma-Derived Cell Line TF274 Is Highly Osteogenic In Vitro and In Vivo 1998 ·Calcified Tissue International ·Uma Prabhakar, Ian E. James, Robert A. Dodds, (unknown), David J. Rieman, David B. Lipshutz, (unknown), Zdenka Jonak, K. B. Tan, F H Drake, Maxine Gowen	21
16	SB 207499 (Ariflo), a Potent and Selective Second-Generation Phosphodiesterase 4 Inhibitor: In Vitro Anti-inflammatory Actions 1998 ·Journal of Pharmacology and Experimental Therapeutics ·Mary S. Barnette, S. Brøgger Christensen, David M. Essayan, Marilyn Grous, Uma Prabhakar, Jonathan Rush, A. Kagey-Sobotka, Theodore J. Torphy	116
17	Inhibition of LPS-induced TNFα production in human monocytes by adenosine (A2) receptor selective agonists 1995 ·International Journal of Immunopharmacology ·Uma Prabhakar, David P. Brooks, (unknown), Klaus Esser	35
18	Characterization of cAMP-dependent inhibition of LPS-induced TNFα production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor 1994 ·International Journal of Immunopharmacology ·Uma Prabhakar, David B. Lipshutz, Joan O'Leary Bartus, Mark J. Slivjak, Edward F. Smith, John C. Lee, Klaus Esser	122
19	Inhibition of interleukin-1 (IL-1) and tumor necrosis factor (TNF) production by pyridinyl imidazole compounds is independent of cAMP elevating mechanisms 1993 ·Inflammation Research ·Shouki Kassis, Uma Prabhakar, (unknown)	14
20	Protein kinase C regulates TNF-alpha production by human monocytes. 1993 ·PubMed ·Uma Prabhakar, David B. Lipshutz, M Pullen, H. A. Turchin, Shouki Kassis, P Nambi	29

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact